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room visits was negatively associated with repeat mammography screening. No 
association was observed between county level characteristics such as number of 
primary care physicians, number of mammography screening facilities, and number 
of federally qualified health care centers per 10,000 women and repeat mammog-
raphy screening. ConClusions: Mammography screening is underutilized in the 
Medicaid population. Various factors predicting repeat mammography screening 
were identified. Program planners should consider these factors when designing 
educational interventions aimed at increasing routine use of mammography screen-
ing among Medicaid enrollees.
PCN181
ONCOlOgy PriCiNg TreNds iN The UNiTed sTaTes aNd The UNiTed 
KiNgdOm (2011-2013)
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: To understand relative price differential for cancer drugs in the U.S. 
and the U.K. Develop implications for pricing strategy and patient access for cancer 
drugs. Methods: Ten branded cancer drugs were selected and their prices for simi-
lar dose and packaging were compared in the U.S. and the U.K. Prices were analyzed 
for the end of 2011 and 2012. Historical exchange rates were used to convert British 
pounds to US dollars. Relative price discount was calculated for all selected cancer 
drugs. KOLs and payers were interviewed to understand current and future implica-
tions of this price differential. Results: The median price discount for selected ten 
branded cancer drugs in the UK versus the United States was ~50%. The range of 
discount for 10 branded cancer drugs was 27%-61%. The price discount for oral small 
molecule drugs was higher than for biologics (55% vs. 45%). Since the U.K. is one of 
the few remaining free pricing markets in Europe, other European markets are likely 
to have even higher discounts relative to the prices in the U.S. Due to rising coinsur-
ance of specialty products, U.S. cancer patients bear significantly higher costs than 
patients in the UK. KOL and payer interviews suggest U.S. pricing trends for cancer 
drugs are unlikely to be sustained at this level in the future. ConClusions: U.S. 
cancer drug prices are significantly higher than the prices in the U.K. This price 
differential is unlikely to be sustained in the future.
PCN182
aN aPPraisal Of PCOdr’s deCisiONs aNd iNflUeNCe Over The lasT 3 
years
Joinnides M.1, Beckerman R.2
1CBPartners, San Francisco, CA, USA, 2CBPartners, New York, NY, USA
objeCtives: The purpose of this study was to understand pCODR’s impact on pro-
vincial formulary decisions since its establishment in 2010. Methods: 29 pCODR 
reviews were analysed. The agency publishes its reviews on its website, www.pcodr.
ca, including final recommendations for provinces to consider in their respective 
formularies. pCODR also publishes a “Provincial Funding Summary” of 9 provinces 
(all except Québec) following each of its final recommendations when available. 
pCODR’s recommendations were indexed with corresponding provincial decisions 
in order to measure the frequency with and degree to which provinces follow pCODR 
guidance. Results: Out of the 29 final recommendations analysed, pCODR has 
issued 24 positive funding recommendations, including 20 “conditional on cost-
effectiveness being improved.” Given the 24 positive recommendations, provinces 
funded products with similar or more restrictiveness than pCODR’s recommenda-
tion 21.3% of the time and with less restrictiveness 6.9% of the time; provinces 
remained under consideration, negotiation, or lacked any status update 71.8% of 
the time. No province has rejected funding of an oncology product following a 
positive pCODR recommendation. pCODR issued negative funding recommenda-
tions 5 of 29 times. Of these, provinces have almost never funded the product in 
turn. ConClusions: Provinces have tended to follow pCODR’s recommendations 
or not make a decision. Compared to other provinces, Alberta tends to fund prod-
ucts with fewer restrictions than pCODR recommends, while Ontario demonstrates 
more restrictiveness. Saskatchewan has followed pCODR most closely. Manitoba, 
New Brunswick, Newfoundland and Labrador, and Prince Edward Island respond 
most slowly, in “consideration” or “negotiation” of most pCODR recommendations.
PCN183
effeCTs Of The Primary Payer TyPe aNd raCe/eThNiCiTy ON PrOsTaTe 
CaNCer sCreeNiNg PraCTiCes dUriNg PreveNTive healTh exams iN 
UNiTed sTaTes ambUlaTOry Care seTTiNgs
Jayasekera J., Onukwugha E.
University of Maryland School of Pharmacy, Baltimore, MD, USA
objeCtives: There is limited information on the relationship between insur-
ance coverage and prostate cancer(PCa)-screening practices among race/ethnic 
minorities in ambulatory care settings in the US. The objective of this study was 
to determine whether the observed race/ethnicity differences in prostate-specific 
antigen(PSA)-screening for PCa may be explained by differences in insurance 
coverage. Methods: We analyzed a nationally representative sample of visits to 
office-based physicians’ practices from 2005-2010 using the National Ambulatory 
Medical Care Survey (NAMCS). The sample consisted of outpatient visits for preven-
tive health exams (PHEs) of men aged 40 years and above, without PCa. The primary 
insurance payer categories were mutually exclusive and included the following: 
Medicare, Medicaid, private insurance and other types. Information on the receipt 
of PSA-screening, demographics, physician specialty and type of office setting were 
collected. Generalized estimating equations were used to investigate the effect of 
race and insurance type on PSA-screening. Results: Application of the inclusion 
criteria resulted in 5,829 office-visits for PHEs. Majority (57%) of the sample was aged 
below 66 years, 10% were African Americans and 9% Hispanics. Over 47% were cov-
ered by private insurance, 39% by Medicare and 5% Medicaid. Overall, 16% received 
PSA-screening during a PHE. Hispanics (prevalence ratio:0.62,95%CI:0.43-0.90) and 
Medicaid (prevalence ratio:0.24, 95%CI:0.11-0.55) patients were less likely to receive 
PSA-screening compared to Whites and patients with private insurance. PHEs 
surgery at any time during the study period was present in 94.5%, 91.2%, and 65.9% 
of patients, respectively (5.5% of patients had no claims indicating any prior cancer 
treatment). Mean length of chemotherapy treatment was 806 days, and 571 days for 
biologic treatment. ConClusions: Patients initiated on regorafenib were largely 
suffering from metastatic cancer, and had a range of comorbid conditions. Nearly 
all patients were treated with chemotherapy and/or biologic agents before initiat-
ing regorafenib treatment.
PCN178
Use Of bONe-mOdifyiNg ageNTs fOllOwiNg aNdrOgeN dePrivaTiON 
TheraPy fOr mediCare NON-meTasTaTiC PrOsTaTe CaNCer PaTieNTs
Yong C.1, Onukwugha E.1, Mullins C.D.1, Zuckerman I.H.1, Hussain A.2, Naslund M.2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School 
of Medicine, Baltimore, MD, USA
objeCtives: Guidelines on the management of cancer treatment-induced bone 
loss (CTIBL) in men receiving androgen deprivation therapy (ADT) for prostate can-
cer (PC) recommend bisphosphonate (BP) therapy or other bone-modifying agents 
(BMAs). There is limited information on the use of BMAs for CTIBL in men with PC. 
We examined BMA utilization patterns following ADT initiation among elderly men 
with non-metastatic PC. Methods: Using linked Surveillance, Epidemiology, and 
End Results (SEER) & Medicare data, we identified men aged 66+ with incident non-
metastatic PC diagnosed during 2007-2009, with claims from 2006-2010. Patients 
received ADT within 6 months after diagnosis and had at least 6 months of Part D 
enrollment during follow-up. Multivariable logistic regression model was estimated 
to identify demographic and clinical factors associated with BMA utilization fol-
lowing ADT initiation. Results: We identified 7,545 non-metastatic PC patients 
who received ADT (median age: 74). The sample included patients with stage 2 
(80%), 3 or 4 (8%), or unstaged (12%) PC. Overall, 8.6% had any BMA use after ADT 
initiation and the most common BMAs were oral BP (5.2%), intravenous BP (3.3%), 
followed by calcitonin (0.5%). A small proportion (1.6%) of the sample had any BMA 
use prior to ADT initiation. The median time to first BMA use after ADT initiation 
was 189 days. Factors associated with statistically significant increased likelihood 
of BMA use were older age, poorly differentiated tumor, and presence of osteo-
porosis. Compared to stage 2 PC patients, those with stages 3 or 4, and unstaged 
PC were more likely to receive BMA (p< 0.01). Patient race/ethnicity, comorbidity 
profile, and history of fracture were not statistically significantly associated with 
BMA receipt. ConClusions: Less than 10% of elderly men diagnosed with non-
metastatic PC and initiating ADT received any BMA, suggesting that a significant 
gap remains in the prevention and treatment of CTIBL in this population.
PCN179
The dOwNward TreNd iN ONCOlOgy drUg PriCiNg, sPeed TO marKeT 
aNd aCCess
Colasante W.1, Alexander R.1, Clark J.1, Hickson S.1, Li X.2
1IMS Consulting Group, Cambridge, UK, 2University of Cambridge, Cambridge, UK
objeCtives: Quantify the price, time and volume concessions incurred by manu-
facturers launching new oncology drug treatments across the EU5 in order to gain 
market access Methods: We analyzed launches of innovative oncology products 
in both the US and EU5 since 2005 (n= 23). Two cohorts (2005-08; 2009-2013) were 
defined where we analyzed price, volume and access time. We created an overall 
opportunity index combining these 3 variables. Prices (MSP – Midas) were made rela-
tive to the US price. Time to access: 2 points were measured – time from regulatory 
approval to price approval by authorities where applicable and time to first reported 
sales. Volume was assessed as units sold over the period cohort, normalized by the 
local epidemiology Results: Price, time to access and volume are all worsening 
for all EU markets compared to the US. The overall combined opportunity index has 
declined or remained low and flat in France (1.22 – 0.93), Germany (0.80 – 0.75), Italy 
(0.45 – 0.46), Spain (0.67 – 0.39) and UK (0.54 – 0.57). US = 1. ConClusions: Ongoing 
EU health care budget management have been modifying the relative commercial 
attractiveness compared to the US of many products including new oncology com-
pounds in Europe. The EU empirical mindset of trading off price to gain faster access 
to market with no or minimal concession on the usage is not supported by the data. 
For a health care perspective, the under usage of oncology products potentially and 
directly impacting overall survival of the patient compared to the US may potentially 
lead to a lower survival in EU compared to the US. Epidemiologists may only able to 
detect this consequence in the coming years.
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faCTOrs assOCiaTed wiTh rePeaT mammOgraPhy sCreeNiNg iN The 
mediCaid POPUlaTiON
Mahabaleshwarkar R.1, Khanna R.1, Banahan B.F.1, West-Strum D.1, Yang Y.1, Hallam J.2
1University of Mississippi, University, MS, USA, 2Kent State University, Kent, OH, USA
objeCtives: Limited information currently exists regarding use of routine mam-
mography screening among Medicaid enrollees. The current study determined 
the prevalence of repeat mammography screening and the associated factors in 
the Medicaid population. Methods: The 2006-2008 Medicaid Analytic Extract 
(MAX) data for 39 states in the United States were used in this study. The target 
population consisted of female recipients aged 40-64 years who were continuously 
enrolled in the Medicaid program during 2006-2008. Recipients with a diagnosis 
of breast cancer were excluded from the study. Repeat mammography screening 
was defined as receipt of two successive mammograms during the study period 
with a gap of 10-14 months. The effect of various recipient- and county-level fac-
tors on repeat mammography screening was determined using hierarchical logistic 
regression. Results: Approximately 1.19% of the recipients received repeat mam-
mograms during the study period. The repeat mammography screening rates were 
higher in older women and those belonging to ethnic minorities than younger 
women and whites. Number of visits to physician offices and outpatient centers, 
hormone replacement therapy, and routine cervical cancer screening were positively 
associated with repeat mammography screening. However, number of emergency 
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randomized controlled trials (RCTs), with 19 including OS as an endpoint. Seven of 
these 19 indications had statistically significant OS data based on the most recent 
data cut included in the manufacturer’s submission to pCODR, while the remaining 
12 either did not have statistically significant OS data or the OS data were immature 
(i.e., median OS not yet reached) at the time of submission. More than half of the 12 
submissions with non-significant OS trial data allowed cross-over in the trial (n= 9) 
thereby potentially confounding the clinical benefit of the active therapy. Of the 19 
positive recommendations which had an RCT design and assessed OS as an endpoint, 
progression-free survival (PFS) was statistically significant with or without additional 
clinically or statistically significant secondary endpoints. ConClusions: This study 
highlights that positive pCODR recommendations may be made in the absence of a 
clear OS benefit, provided strong PFS and or additional endpoint data exist.
PCN190
iNsighTs iNTO The PaN-CaNadiaN ONCOlOgy drUg revew 
reCOmmeNdaTiONs - Three years afTer iTs iNCePTiON
Samjoo I.A.1, Grima D.T.2
1Cornerstone Research Group Inc., Burlington, ON, Canada, 2Cornerstone Research Group, 
Burlington, ON, Canada
bACkgRound: In 2010, the permanent national oncology-specific drug review pro-
cess, pan-Canadian Oncology Drug Review (pCODR), was established to assess the 
clinical evidence and cost-effectiveness of new cancer drugs and provide recom-
mendations to the provinces (except Quebec) and territories to guide their drug 
funding decisions. objeCtives: This study sought to identify characteristics and 
decision patterns of the pCODR recommendations. Methods: Twenty-eight rec-
ommendations, covering 33 requested populations, publicly accessible at www.
pcodr.ca were reviewed since pCODRs operation: 13 July 2011 - 9 December 2013. 
Additional information was obtained from the www.reimbursementdecisions.com 
database. Results: Of the twenty-four positive recommendations for coverage, 
three suggested a more limited patient population than the one requested. Four 
population funding requests received positive recommendations for the requested 
population without conditions. In seventeen cases, positive recommendations for 
the requested population were made conditional on improvement of cost-effective-
ness ratios. Nine negative recommendations were made due to: a) limitations in evi-
dence from phase two trials; b) modest progression-free survival, lack of statistically 
significant overall survival, lack of quality of life data and poor cost-effectiveness, 
and/or; c) unclear clinical benefit and an unacceptable cost-effectiveness model. 
Many economic reviews by pCODR included re-analyses of the cost-effectiveness 
ratios which in some cases had substantial impact on cost-effectiveness. The most 
common changes from the submitted analyses where limiting product benefit 
post-progression, time horizon reductions, or changes to post-progression mortal-
ity risk. ConClusions: Most submissions resulted in a positive funding recom-
mendation. The positive conditional pCODR recommendations support a continued 
provincial product listing agreement structure that includes rebates to lower cost-
effectiveness. The economic re-analyses of the post-progression survival benefit 
indicates a need for manufacturers to provide comprehensive consideration of 
uncertainty surrounding such benefits in the submitted cost-effectiveness analysis.
PCN191
lessONs fOr adaPTive liCeNsiNg: aNalysis Of CONdiTiONally aPPrOved 
ema COmPOUNds, Their reimbUrsemeNT sTaTUs aNd regUlaTOry/
reimbUrsemeNT daTa reqUiremeNTs
Spearpoint P.A., Yip C.Y., Zhang W.
Pope woodhead and Associates, Cambridgeshire, UK
objeCtives: Understand how conditionally approved (CA) compounds in the EMA 
have performed in reimbursement assessment. Findings will inform current adap-
tive licensing initiatives. Methods: EMA EPAR reports were analysed to identify 
CA compounds from 2006−2013. HTA reports from national reimbursement authori-
ties of the UK (NICE, SMC), France (HAS), Germany (G-BA) and Italy (AIFA) were also 
analysed to understand reimbursement status of these products. Results: 20 CA 
compounds were identified: 11 with current CA status, 7 fully approved and 2 with-
drawn. Approval was based upon strength of clinical data from PII/PIII studies. In 
France, 86% of CA indications were reimbursed, most with an ASMR V. In Italy, 62% 
of CA indications were reimbursed. Risk sharing agreements (RSA) were used in at 
least 38% of approvals. In Germany, approximately 50% of CA products licensed after 
AMNOG were reimbursed. In the UK, only 6 CA products received a positive NICE 
recommendation, 5 under RSAs to fulfil the cost-effectiveness criteria. CA is granted 
on limited clinical evidence. Countries using a therapeutic-benefit assessment (e.g. 
France) reimbursed more CA compounds than cost-effectiveness (CE) driven coun-
tries (e.g. UK). RSA is a key tool to win reimbursement in cost-effectiveness countries 
where high ICER thresholds impeded reimbursement (Bosutinib) or insufficient clini-
cal data (Pixantrone). Positive reimbursement decisions were driven by robust clinical 
data in orphan or small indications with limited therapies. Strategies employed by 
companies to overcome payer concerns include: 1) Initial restriction of compound 
approval to small high unmet need subpopulations; 2) Performance or financial risk 
sharing arrangements; 3) On-going evidence development plans. ConClusions: 
Reimbursement outcomes for CA compounds are variable across the EU. This is due 
to either clinical or economic uncertainties from evidence produced. To deal with 
these uncertainties, agreed mechanisms for continual evidence development and RSA 
implementations should be incorporated into on-going adaptive licensing initiatives.
PCN192
COrrelaTiON Of hTa deCisiON OUTCOmes iN fraNCe aNd germaNy
Sun D.1, Beckerman R.1, Bustamante M.M.D.2
1CBPartners, New York, NY, USA, 2CBPartners, Basel, Switzerland
objeCtives: The objective of this study is to compare the HTA decisions of oncology 
products in France and Germany and provide insight into the most important asset 
value attributes that characterise a positive appraisal in these markets. Methods: 
We analysed the G-BA and the HAS assessments of 11 oncology products published 
conducted in health maintenance organizations were more likely to have a PSA-
screening, compared to physician group settings. General practitioners were more 
likely to receive PSA-screening compared to other types of specialists. Interactions 
between race and insurance type were not significant. ConClusions: Hispanics 
and individuals insured by Medicaid are less likely to receive PSA-screening dur-
ing an ambulatory care office-visit for a PHE. Efforts to improve access to cancer-
screening services are warranted for these groups. It is necessary to consider the 
differential impact of PCa-screening policies on medically underserved populations.
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CaNCer Care COsTs TreNd iN The UNiTed sTaTes: fiNdiNgs frOm The 
mediCal exPeNdiTUre PaNel sUrvey 2008-2011
Haider M.R.1, Qureshi Z.1, Salloum R.1, Heidari K.2, Xirasagar S.1, Bennett C.1, Khan M.M.1
1University of South Carolina, Columbia, SC, USA, 2Department of Health and Environmental 
Control, Columbia, SC, USA
objeCtives: To estimate the annual financial burden of cancer care in the 
United States and to study the effects of cancer on total health care of the coun-
try. Methods: Direct medical cancer care costs of for the years 2008-2011 were 
estimated using the household component of the Medical Expenditure Panel Survey 
(MEPS), a nationally representative survey that includes self-reported health care 
utilization and expenditures for the US civilian non-institutionalized population. 
The likelihood of having a cancer diagnosis by age, race and insurance status and 
other variables were also assessed. Results: Aggregate cost of cancer in the US 
increased from $183 billion in 2008 to $236 billion in 2011. While total out-of-pocket 
(OOP) costs per cancer case decreased from $1,419.43 in 2008 to $1,254.77 in 2011, 
total cost per-case increased from $10,461.66 to $12,583.69 over 2008 to 2011. The 
OOP and total medical care expenditures per case in 2008 were $1,560.54 and 
$11501.69 respectively in 2011 prices using Urban Medical Consumer Price Index. 
OOP per case declined at an annual rate of 7.3% while the total direct cost increased 
at an annual rate of about 3%. Whites, females and 45-64 year olds were more likely 
to have a cancer diagnosis and most cancer care costs were covered by private insur-
ers. Geographical location was not associated with cancer diagnosis although the 
southern region has the highest concentration. ConClusions: Our study confirms 
that cancer is a significant cost driver of the US health care system. Due to expected 
increase in the number of incident cases and survival rate, total cost of cancer is 
likely to increase rapidly over the next decade. With the implementation of the 
Affordable Care Act, burden of cancer care costs on taxpayers will increase due to 
higher insurance coverage and lower OOP cost.
PCN188
aN ONliNe PaTieNT-OrieNTed radiaTiON risK assessmeNT TOOl TO 
PrOjeCT CaNCer risK fOllOwiNg exPOsUre TO lOw–iONiziNg radiaTiON 
iN CaNada
Zowall H., Brewer C., Deutsch A.
Zowall Consulting Inc., Westmount, QC, Canada
objeCtives: Increasing use of imaging procedures has raised concerns about the 
risk of cancer due to repeated exposure to low-ionizing radiation. We developed an 
online radiation risk assessment tool to project the lifetime attributable risk (LAR) 
of cancer incidence following repeated exposure to imaging procedures. Methods: 
We developed a risk projection model to assess radiation exposure from imaging 
procedures, to estimate the lifetime attributable risk (LAR) of cancer incidence and 
95% uncertainty limits (UL), according to age, gender, and imaging type. We used the 
“linear no-threshold” models (extrapolation of risk associated with high-dose ion-
izing radiation to low-dose exposure). The model has been adjusted using Canadian 
data to reflect the Canadian population. Results: Selected simulation results are 
presented. The LAR of cancer incidence for a 50 and 70 year old male, exposed to 
a single coronary angiogram is 11 (95% UL: 6-22) and 6 (3-12) per 10,000 exposed, 
respectively. As the number of coronary angiograms increased from one to five over 
time, the cancer risk increased to 54 (27-106) and 26 (14-52) per 10,000, respectively. 
As age increases the excess lifetime risk of cancer decreases. The excess lifetime risk 
of cancer is higher for females than for males. The LAR of cancer for a 70 year old 
male and female, exposed to a computed tomography (CT) for suspected stroke is 4 
(2-8) and 5 (3-10) per 10,000, respectively. As the number of CT scans increased from 
one to five, the total risk of cancer increased to 17 (8-33) and 23 (12-43) per 10,000, 
respectively. ConClusions: Patients are rarely aware of radiation risk. Physicians 
often underestimate the magnitude of radiation doses arising from imaging proce-
dures. An online, interactive model might facilitate the decision making process, 
leading to more informed decisions and improved clinical outcomes.
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reimbUrsemeNT reCOmmeNdaTiONs fOr CaNCer PrOdUCTs wiThOUT 
sTaTisTiCally sigNifiCaNT Overall sUrvival daTa: a review Of 
CaNadiaN PCOdr deCisiONs
Heyland K.1, Samjoo I.A.2, Grima D.T.1
1Cornerstone Research Group, Burlington, ON, Canada, 2Cornerstone Research Group Inc., 
Burlington, ON, Canada
objeCtives: Overall survival (OS) data for cancer products is an important end-
point to payers. This study sought to examine (1) what proportion of positive reim-
bursement recommendations by the pan-Canadian Oncology Drug Review (pCODR) 
occurred despite unavailable statistically significant overall survival data, and (2) 
the proportion of negative recommendations that noted a lack of overall survival 
data as a contributing factor. Methods: Recommendations publicly accessible at 
www.pcodr.ca and reimbursementdecisions.com were reviewed for the period 13 July 
2011 – 9 December 2013. Results: During this time period, 28 submissions contain-
ing 32 oncology-specific indications were deliberated on by the pCODR committee. 
Of the eight indications that received a negative recommendation, only one had 
statistically significant overall- and progression-free survival data. A total of 24 indi-
cations received positive recommendations. Of these, two were based on single-arm 
Phase II clinical trials. The remaining 22 positive recommendations were based on 
